Helius Medical (HSDT) Stock Forecast, Price Target & Predictions

OverviewRevenue Financials Chart Transcripts

HSDT Stock Forecast

Helius Medical stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

HSDT Analyst Ratings

Buy

According to 3 Wall Street analysts, Helius Medical's rating consensus is 'Buy'. The analyst rating breakdown for HSDT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 16, 2024	Maxim Group	Buy	Reduce	Downgrade
Dec 20, 2022	Maxim Group		Buy	Initialise
Nov 17, 2022	Zacks Investment Research		Buy	Upgrade
Aug 24, 2022	Roth Capital		Buy	Initialise

Row per page

Go to

Helius Medical's last stock rating was published by Maxim Group on Oct 16, 2024. The company Downgrade its HSDT rating from "Buy" to "Reduce".

Helius Medical Financial Forecast

Helius Medical Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	$143.00K	$256.00K	$111.00K	$282.00K	$196.00K	$119.00K	$190.00K	$258.00K	$109.00K	$71.00K	$84.00K	$191.00K	$131.00K	$133.00K	$207.00K	$152.00K	$150.00K	$518.00K	$677.00K
Avg Forecast	$301.00K	$225.00K	$239.00K	$205.00K	$268.00K	$150.00K	$150.00K	$110.00K	$249.67K	$345.00K	$188.33K	$275.00K	$262.33K	$167.50K	$360.00K	$160.00K	$100.00K	$84.50K	$95.00K	$93.50K	$170.00K	$100.00K	$100.00K	$300.00K	$200.00K	$300.00K	$300.00K	$150.00K
High Forecast	$301.00K	$225.00K	$239.00K	$205.00K	$268.00K	$150.00K	$150.00K	$110.00K	$249.67K	$345.00K	$188.33K	$275.00K	$262.33K	$167.50K	$360.00K	$160.00K	$100.00K	$84.50K	$95.00K	$93.50K	$170.00K	$100.00K	$100.00K	$300.00K	$200.00K	$300.00K	$300.00K	$150.00K
Low Forecast	$301.00K	$225.00K	$239.00K	$205.00K	$268.00K	$150.00K	$150.00K	$110.00K	$249.67K	$345.00K	$188.33K	$275.00K	$262.33K	$167.50K	$360.00K	$160.00K	$100.00K	$84.50K	$95.00K	$93.50K	$170.00K	$100.00K	$100.00K	$300.00K	$200.00K	$300.00K	$300.00K	$150.00K
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	0.41%	1.36%	0.40%	1.07%	1.17%	0.33%	1.19%	2.58%	1.29%	0.75%	0.90%	1.12%	1.31%	1.33%	0.69%	0.76%	0.50%	1.73%	4.51%

Helius Medical's average Quarter revenue forecast for Dec 23 based on 2 analysts is $249.67K, with a low forecast of $249.67K, and a high forecast of $249.67K. HSDT's average Quarter revenue forecast represents a 74.59% increase compared to the company's last Quarter revenue of $143.00K (Sep 23).

Helius Medical EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-2.22M	$-3.22M	$-4.97M	$-321.00K	$-4.03M	$-2.98M	$-4.71M	$-4.03M	$-3.98M	$-6.29M	$-3.54M	$-3.37M	$-3.75M	$-3.91M	$-3.08M	$-5.76M	$-5.83M	$-11.40M	$-14.93M
Avg Forecast	$-301.00K	$-225.00K	$-239.00K	$-205.00K	$-268.00K	$-150.00K	$-150.00K	$-110.00K	$-249.67K	$-345.00K	$-188.33K	$-275.00K	$-262.33K	$-167.50K	$-360.00K	$-4.20M	$-100.00K	$-84.50K	$-4.21M	$-93.50K	$-170.00K	$-100.00K	$-100.00K	$-300.00K	$-200.00K	$-300.00K	$-300.00K	$-150.00K
High Forecast	$-301.00K	$-225.00K	$-239.00K	$-205.00K	$-268.00K	$-150.00K	$-150.00K	$-110.00K	$-249.67K	$-345.00K	$-188.33K	$-275.00K	$-262.33K	$-167.50K	$-360.00K	$-3.36M	$-100.00K	$-84.50K	$-3.37M	$-93.50K	$-170.00K	$-100.00K	$-100.00K	$-300.00K	$-200.00K	$-300.00K	$-300.00K	$-150.00K
Low Forecast	$-301.00K	$-225.00K	$-239.00K	$-205.00K	$-268.00K	$-150.00K	$-150.00K	$-110.00K	$-249.67K	$-345.00K	$-188.33K	$-275.00K	$-262.33K	$-167.50K	$-360.00K	$-5.04M	$-100.00K	$-84.50K	$-5.06M	$-93.50K	$-170.00K	$-100.00K	$-100.00K	$-300.00K	$-200.00K	$-300.00K	$-300.00K	$-150.00K
Surprise %	-	-	-	-	-	-	-	-	-	6.43%	17.09%	18.09%	1.22%	24.03%	8.27%	1.12%	40.27%	47.15%	1.49%	37.86%	19.80%	37.46%	39.08%	10.26%	28.79%	19.44%	38.01%	99.55%

undefined analysts predict HSDT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Helius Medical's previous annual EBITDA (undefined) of $NaN.

Helius Medical Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-3.66M	$-1.65M	$-1.08M	$-7.19M	$2.96M	$-4.57M	$-3.91M	$-4.10M	$-4.69M	$-5.98M	$-3.36M	$-2.53M	$-3.48M	$-3.36M	$-4.76M	$-4.80M	$-5.59M	$-186.00K	$1.32M
Avg Forecast	$-1.87M	$-1.95M	$-1.91M	$-3.29M	$-3.29M	$-3.97M	$-1.87M	$-18.85M	$-14.11M	$-22.44M	$-21.82M	$-20.57M	$-24.31M	$-26.44M	$-141.01M	$-4.27M	$-146.05M	$-220.33M	$-4.26M	$-190.11M	$-352.53M	$-396.60M	$-528.80M	$-705.06M	$-925.39M	$-969.46M	$-991.49M	$2.62M
High Forecast	$-1.87M	$-1.95M	$-1.91M	$-3.29M	$-3.29M	$-3.97M	$-1.87M	$-18.85M	$-14.11M	$-22.44M	$-21.82M	$-20.57M	$-24.31M	$-26.44M	$-141.01M	$-3.42M	$-146.05M	$-220.33M	$-3.41M	$-190.11M	$-352.53M	$-396.60M	$-528.80M	$-705.06M	$-925.39M	$-969.46M	$-991.49M	$3.15M
Low Forecast	$-1.87M	$-1.95M	$-1.91M	$-3.29M	$-3.29M	$-3.97M	$-1.87M	$-18.85M	$-14.11M	$-22.44M	$-21.82M	$-20.57M	$-24.31M	$-26.44M	$-141.01M	$-5.12M	$-146.05M	$-220.33M	$-5.11M	$-190.11M	$-352.53M	$-396.60M	$-528.80M	$-705.06M	$-925.39M	$-969.46M	$-991.49M	$2.10M
Surprise %	-	-	-	-	-	-	-	-	-	0.16%	0.08%	0.05%	0.30%	-0.11%	0.03%	0.92%	0.03%	0.02%	1.40%	0.02%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.51%

Helius Medical's average Quarter net income forecast for Dec 22 is $-24.31M, with a range of $-24.31M to $-24.31M. HSDT's average Quarter net income forecast represents a -922.81% decrease compared to the company's last Quarter net income of $2.96M (Sep 22).

Helius Medical SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$2.20M	$2.57M	$2.87M	$1.97M	$3.39M	$2.46M	$2.82M	$2.38M	$2.86M	$4.74M	$2.20M	$2.09M	$2.37M	$2.39M	$2.86M	$3.81M	$4.29M	$3.85M	$4.58M
Avg Forecast	$4.63M	$3.46M	$3.68M	$3.16M	$4.13M	$2.31M	$2.31M	$1.69M	$3.84M	$5.31M	$2.90M	$4.23M	$4.04M	$2.58M	$5.54M	$2.46M	$1.54M	$1.30M	$1.46M	$1.44M	$2.61M	$1.54M	$1.54M	$4.61M	$3.08M	$4.61M	$4.61M	$2.31M
High Forecast	$4.63M	$3.46M	$3.68M	$3.16M	$4.13M	$2.31M	$2.31M	$1.69M	$3.84M	$5.31M	$2.90M	$4.23M	$4.04M	$2.58M	$5.54M	$2.46M	$1.54M	$1.30M	$1.46M	$1.44M	$2.61M	$1.54M	$1.54M	$4.61M	$3.08M	$4.61M	$4.61M	$2.31M
Low Forecast	$4.63M	$3.46M	$3.68M	$3.16M	$4.13M	$2.31M	$2.31M	$1.69M	$3.84M	$5.31M	$2.90M	$4.23M	$4.04M	$2.58M	$5.54M	$2.46M	$1.54M	$1.30M	$1.46M	$1.44M	$2.61M	$1.54M	$1.54M	$4.61M	$3.08M	$4.61M	$4.61M	$2.31M
Surprise %	-	-	-	-	-	-	-	-	-	0.41%	0.89%	0.68%	0.49%	1.32%	0.44%	1.15%	1.54%	2.20%	3.25%	1.53%	0.80%	1.54%	1.56%	0.62%	1.24%	0.93%	0.83%	1.99%

Helius Medical's average Quarter SG&A projection for Dec 23 is $3.84M, based on 2 Wall Street analysts, with a range of $3.84M to $3.84M. The forecast indicates a 75.04% rise compared to HSDT last annual SG&A of $2.20M (Sep 23).

Helius Medical EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-5.49	$-0.00	$-0.04	$-0.26	$0.35	$-1.16	$-1.03	$-1.31	$-2.28	$-2.42	$-1.51	$-1.12	$-2.41	$-2.32	$-7.09	$-6.05	$-7.17	$14.96	$23.85
Avg Forecast	$-0.50	$-0.52	$-0.51	$-0.88	$-0.88	$-1.06	$-0.50	$-5.04	$-3.77	$-6.00	$-5.83	$-5.50	$-6.50	$-10.50	$-56.00	$-56.50	$-58.00	$-87.50	$-80.75	$-75.50	$-140.00	$-157.50	$-210.00	$-280.00	$-367.50	$-385.00	$-393.75	$-446.25
High Forecast	$-0.50	$-0.52	$-0.51	$-0.88	$-0.88	$-1.06	$-0.50	$-5.04	$-3.77	$-6.00	$-5.83	$-5.50	$-6.50	$-10.50	$-56.00	$-56.50	$-58.00	$-87.50	$-80.75	$-75.50	$-140.00	$-157.50	$-210.00	$-280.00	$-367.50	$-385.00	$-393.75	$-446.25
Low Forecast	$-0.50	$-0.52	$-0.51	$-0.88	$-0.88	$-1.06	$-0.50	$-5.04	$-3.77	$-6.00	$-5.83	$-5.50	$-6.50	$-10.50	$-56.00	$-56.50	$-58.00	$-87.50	$-80.75	$-75.50	$-140.00	$-157.50	$-210.00	$-280.00	$-367.50	$-385.00	$-393.75	$-446.25
Surprise %	-	-	-	-	-	-	-	-	-	0.92%	0.00%	0.01%	0.04%	-0.03%	0.02%	0.02%	0.02%	0.03%	0.03%	0.02%	0.01%	0.02%	0.01%	0.03%	0.02%	0.02%	-0.04%	-0.05%

According to 1 Wall Street analysts, Helius Medical's projected average Quarter EPS for Dec 22 is $-6.50, with a low estimate of $-6.50 and a high estimate of $-6.50. This represents a -1957.14% decrease compared to HSDT previous annual EPS of $0.35 (Sep 22).

Helius Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HSDT	Helius Medical	-	-	1062.79%	Buy
RPID	Rapid Micro Biosystems	-	-	620.72%	Hold
AZYO	Elutia	-	-	587.92%	Buy
BJDX	Bluejay Diagnostics	-	-	185.71%	Buy
SGHT	Sight Sciences	-	-	139.36%	Hold
HSCS	Heart Test Laboratories	-	-	14.50%	Buy

HSDT Forecast FAQ

Is Helius Medical a good buy?

Yes, according to 3 Wall Street analysts, Helius Medical (HSDT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of HSDT's total ratings.

What are Helius Medical's analysts' financial forecasts?

Helius Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $678K (high $678K, low $678K), average EBITDA is $-678K (high $-678K, low $-678K), average net income is $-27.98M (high $-27.98M, low $-27.98M), average SG&A $10.44M (high $10.44M, low $10.44M), and average EPS is $-7.48 (high $-7.48, low $-7.48). HSDT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $970K (high $970K, low $970K), average EBITDA is $-970K (high $-970K, low $-970K), average net income is $-9.015M (high $-9.015M, low $-9.015M), average SG&A $14.93M (high $14.93M, low $14.93M), and average EPS is $-2.41 (high $-2.41, low $-2.41).

Did the HSDT's actual financial results beat the analysts' financial forecasts?

Based on Helius Medical's last annual report (Dec 2023), the company's revenue was $644K, which missed the average analysts forecast of $1.06M by -39.13%. Apple's EBITDA was $-12.428M, beating the average prediction of $-1.058M by 1074.67%. The company's net income was $-8.85M, missing the average estimation of $-78.952M by -88.79%. Apple's SG&A was $9.27M, missing the average forecast of $16.29M by -43.08%. Lastly, the company's EPS was $-0.0146, missing the average prediction of $-21.107 by -99.93%. In terms of the last quarterly report (Sep 2023), Helius Medical's revenue was $143K, missing the average analysts' forecast of $345K by -58.55%. The company's EBITDA was $-2.218M, beating the average prediction of $-345K by 542.90%. Helius Medical's net income was $-3.663M, missing the average estimation of $-22.444M by -83.68%. The company's SG&A was $2.2M, missing the average forecast of $5.31M by -58.66%. Lastly, the company's EPS was $-5.49, missing the average prediction of $-6 by -8.50%